While large-cap stocks offer stability, their massive scale often limits growth. We analyze three market leaders, identifying one with compelling potential and two where the current story may be fully priced in.
Morgan Stanley and Evercore ISI reaffirm bullish ratings on iRhythm, citing strong Q4 preliminary results and growth potential from its next-gen cardiac monitoring technology.
Despite near-term headwinds in its Nutrition segment, Abbott Laboratories (ABT) maintains a bullish long-term outlook with solid organic sales growth projected for 2026, even as major analysts adjust their price targets following Q4 results.
Doctors Without Borders (MSF) has definitively rejected an Israeli order to hand over sensitive staff information, following months of failed negotiations. The move comes amid a wider crackdown on aid groups and a devastating toll on healthcare workers in the conflict.
Shares of life sciences toolmaker Qiagen (NYSE:QGEN) have shown renewed momentum, gaining over 12% in the past month. This surge brings the company's valuation into sharp focus, with analysts divided between near-term earnings multiples and long-term cash flow projections.
Becton Dickinson announces a major spin-off of its Biosciences unit to combine with Waters Corporation, alongside a successful pilot to recycle polystyrene labware, signaling a dual push towards portfolio focus and sustainability.
As economic anxieties mount, strategic diversification remains paramount. We examine two Vanguard ETFs that could offer stability and long-term growth opportunities should market conditions deteriorate.
TD Cowen and H.C. Wainwright have raised price targets on KalVista Pharmaceuticals, expressing confidence in its oral hereditary angioedema treatment ahead of the company's fourth-quarter financial results.
In a strategic reshuffle following the exit of its product chief, Netflix has merged its product and technology divisions under veteran executive Elizabeth Stone, signaling a tighter integration of engineering and user experience.
Craig-Hallum and Northland Securities have both lowered price targets for MiMedx Group (MDXG), citing near-term uncertainty following new CMS billing guidance for skin substitute products, though both firms maintain positive long-term ratings.
A significant reset in analyst price targets for iRhythm Holdings (IRTC) is prompting investors to reassess the cardiac monitoring firm's risk-reward profile. This shift reflects evolving views on reimbursement headwinds, competitive pressures, and long-term growth catalysts in the digital health sector.
Novo Nordisk launches its first oral GLP-1 weight-loss drug with strong early demand, reports positive Phase 3 results for CagriSema, and expands a cell therapy partnership for diabetes. These moves come as investors reevaluate the company's long-term growth prospects amid competitive and pricing pressures.
As inflation persists, Baby Boomers are leveraging decades of financial experience to cut costs strategically. We examine the key spending categories they avoid and the generational mindset behind their money choices.
CNBC's Jim Cramer tempered enthusiasm for Novo Nordisk stock, suggesting investors hold rather than buy after its massive gains driven by blockbuster weight-loss drugs.
Despite modest nominal gains, real wages for U.S. workers are failing to keep pace with the cost of living, with a majority reporting financial strain as structural economic shifts and technological efficiencies redirect gains away from paychecks.
AbbVie's stock presents a complex picture for investors, with recent mixed performance contrasting sharply with its robust multi-year returns. As shares trade below consensus targets, the market weighs near-term headwinds against the pharmaceutical giant's proven track record and pipeline potential.
BioNTech's stock faces pressure following a Leerink Partners downgrade, which tempered near-term optimism around its oncology pipeline after a recent rally. The move highlights investor reassessment of catalysts amid mixed long-term performance.
The surge in popularity of weight-loss drugs like Ozempic and Wegovy is sending shockwaves far beyond the pharmacy, fundamentally altering consumer spending, challenging major corporations, and forcing a broad economic recalibration.
IDEAYA Biosciences shares have retreated from recent highs, sparking debate among investors. While a discounted cash flow model suggests deep undervaluation, price-to-sales metrics paint a contrasting picture of a premium stock. We examine the numbers behind the volatility and what it signals for the precision oncology company's future.
While Wall Street chases the latest weight-loss drug headlines, Novo Nordisk's recent launch of an oral GLP-1 therapy and its entrenched insulin business present a compelling value proposition for long-term investors.
